Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

In RCT (n=210), primary skin fibrosis endpoint was not met, whilst findings for secondary endpoint of FVC% predicted indicate tocilizumab might preserve lung function in people with early systemic sclerosis-associated interstitial lung disease and elevated acute-phase reactants.


The Lancet Respiratory Medicine